April 29, 2026 · Casper, WY (registered)
Nightbox LLC Initiates Provisional Patent Filing for Chimeric NKG2D-LIF6 Receptor-Effector Construct
Nightbox LLC has begun preparation of a provisional patent application covering its chimeric receptor-effector platform combining the human NKG2D extracellular domain with the elephant LIF6 effector. The 2,123 bp construct represents a clean intellectual property position, with no prior art identified on the specific combination during a comprehensive freedom-to-operate analysis. Drafting and filing are in progress.
The provisional filing covers method-of-treatment claims for solid tumor oncology applications, composition-of-matter claims on the chimeric construct, and downstream use cases including biothreat-response repurposing of the modular recognition domain.
April 22, 2026 · Casper, WY (registered)
Nightbox LLC Completes In Silico Validation of NKG2D-LIF6 Chimera
Nightbox completed computational validation of the NKG2D-LIF6 construct. Modeling indicates a tumor growth inhibition ceiling of approximately 99 percent on colorectal cancer (CRC) syngeneic models. Selectivity ratios exceed three orders of magnitude favoring tumor over healthy tissue, based on integrated MICA/MICB expression atlases.
Folding stability of elephant LIF6 in human cellular context was confirmed through AlphaFold predictions refined with Rosetta. The construct will proceed to in vivo validation in syngeneic murine models in Q2 2026.
February 8, 2026 · Casper, WY (registered)
Nightbox LLC Founded in the Los Angeles area
Nightbox LLC was incorporated in Wyoming with a mandate to develop first-in-class chimeric receptor-effector gene therapy constructs for solid tumor oncology. The company operates with a single technical founder and a production AI agent stack as its core research infrastructure.